KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Travere Therapeutics (TVTX) EBIAT (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed EBIAT for 15 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIAT rose 104.46% year-over-year to $2.7 million, compared with a TTM value of -$25.5 million through Dec 2025, up 92.06%, and an annual FY2025 reading of -$25.5 million, up 92.06% over the prior year.
  • EBIAT was $2.7 million for Q4 2025 at Travere Therapeutics, down from $25.7 million in the prior quarter.
  • Across five years, EBIAT topped out at $150.7 million in Q3 2023 and bottomed at -$136.1 million in Q1 2024.
  • Average EBIAT over 5 years is -$49.5 million, with a median of -$63.5 million recorded in 2022.
  • The sharpest move saw EBIAT plummeted 6766.71% in 2021, then skyrocketed 279.31% in 2023.
  • Year by year, EBIAT stood at -$88.8 million in 2021, then increased by 25.85% to -$65.8 million in 2022, then tumbled by 34.6% to -$88.6 million in 2023, then surged by 30.94% to -$61.2 million in 2024, then skyrocketed by 104.46% to $2.7 million in 2025.
  • Business Quant data shows EBIAT for TVTX at $2.7 million in Q4 2025, $25.7 million in Q3 2025, and -$12.8 million in Q2 2025.